SERMION® [Nicergoline]

Dosage and administration

The dug is taken orally.

Chronic cerebral circulatory disorders, vascular cognitive impairment, post-stroke states: 10 mg 3 times/day. The therapeutic effect of the drug is developing gradually and treatment course should be at least 3 months.

Vascular dementia: 30 mg 2 times/day. In this case the patient is recommended every 6 months to consult with your doctor about whether to continue therapy.

Peripheral blood flow disorders: 10 mg 3 times/day for a long time (several months).

Contraindications

Hypersensitivity to nicergoline, heavy bleeding, acute myocardial infarction, orthostatic [postural] hypotension, expressed bradycardia, pregnancy, lactation period, and children under 18 years old.

Side effects

In very rare cases, clinically irrelevant side effects were noted: Hypotension and dizziness, very slight gastric distress, flushing, sleepiness and insomnia.

Overdose

Symptoms: hypotension.

Treatment: You should take the horizontal position for a few minutes.

Drug Interactions

Potentiate action of antihypertensive drugs.

Precautions

Caution should be used in administering Sermion in patients with hyperuricemia or with a history of gout and/or under treatment with drugs that might be able to interfere with the metabolism and excretion of uric acid. Sermion may potentiate the effect of antihypertensive drugs.

Country of Manufacture: the USA

You can read the full instruction here

Availability: in stock

Nicergoline is an ergot derivative used primarily to treat senile dementia and other disorders which are known to have a vascular origin. It is known to decrease vascular resistance and increase arterial blood flow within the brain, thus improving the utilization of oxygen and glucose uptake by brain cells.

Here you can read more Metabolic Alchemy Review of Sermion

Country of Manufacture: the USA

  1. Saletu et al (2014) Safety of Nicergoline as an Agent for Management of Cognitive Function Disorders https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163411/
  2. Winblad et al (2008) Therapeutic use of nicergoline https://www.ncbi.nlm.nih.gov/pubmed/18666801
  3. M Fioravanti, L Flicker (2001) Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment https://www.ncbi.nlm.nih.gov/pubmed/11687175
  4. J Kugler, H Heidrich (1984) Nicergoline and cerebral performance insufficiency. Observations in 1 year treatment controls https://www.ncbi.nlm.nih.gov/pubmed/6392047
  5. Fioravanti et al (2014) A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120366/
  6. Saletu et al (2014) Safety of nicergoline as an agent for management of cognitive function disorders https://www.ncbi.nlm.nih.gov/pubmed/25243157
  7. Popova et al (2017) The use nicergoline in the treatment of diabetes mellitus https://www.ncbi.nlm.nih.gov/pubmed/28902812
  8. Felisati et al (2004) Nicergoline in the treatment of dizziness in elderly patients. A review https://www.ncbi.nlm.nih.gov/pubmed/15207410
  9. Voronina et al (1988) Effect of nicergoline on learning and memory https://www.ncbi.nlm.nih.gov/pubmed/3419247
  10. K Shintomi (1991) Pharmacological study of nicergoline. Effects on regional cerebral blood flows and arterial carbon dioxide and oxygen pressure and pH in rats under cyanide-induced histotoxic anoxia https://www.ncbi.nlm.nih.gov/pubmed/1796914
  11. Nakashima et al (2011) Nicergoline improves dysphagia by upregulating substance P in the elderly https://www.ncbi.nlm.nih.gov/pubmed/21694649
  12. Dikova et al (1990) Rheoencephalographic and electroencephalographic studies on nicergoline https://www.ncbi.nlm.nih.gov/pubmed/2232965
  13. Walford et al (2016) Nicergoline inhibits human platelet Ca2+signalling through triggering a microtubule‐dependent reorganization of the platelet ultrastructure https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813371/
  14. Bottiger et al (1996) Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans https://www.ncbi.nlm.nih.gov/pubmed/8971425
  15. Mizuno et al (2005) Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes https://www.ncbi.nlm.nih.gov/pubmed/16325157


Type: Nootropics




CUSTOMERS WHO BOUGHT THIS PRODUCT ALSO BOUGHT